DB18253InvestigationalGene Therapies
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
- Also known as
- Adeno-associated virus serotype 9 vector encoding the Dok7 protein
- Code names
- AMP-101
What you can answer from here — as of September 28, 2026
Which companies are running trials of AMP-101, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account